Recombinant RabMAb®: Reliable antibodies for reproducible results
Jan 28, 2022
Poorly characterized antibodies often fail to provide consistent, reproducible results, thereby wasting materials, researcher time, and money. Compared to traditional polyclonal and monoclonal antibodies, recombinant antibodies exhibit very little batch-to-batch variability, providing scientists with highly reproducible results. In this white paper, we will showcase the reproducibility of recombinant antibodies by assessing the batch-to-batch consistency of the recombinant RabMab anti-PD-L1 antibody [28-8] (ab205921) across various applications, including IHC, ICC, flow cytometry, and western blot. Our results demonstrate high reproducibility between different batches of the recombinant anti-PD-L1 antibody tested in four different applications (IHC, ICC, flow cytometry, and western blot). Batch-to-batch reproducibility of recombinant antibodies overcomes the need for extensive downstream standardization assays saving time, cost, and/or resources. Consistency in the batch performance of recombinant antibodies ensures the longevity and reproducibility of research results generated with these reagents.
- Preclinical Optimization and Safety Studies of a New Lentiviral Gene Therapy for p47phox-Deficient Chronic Granulomatous Disease
- High-Throughput In Vitro, Ex Vivo, and In Vivo Screen of Adeno-Associated Virus Vectors Based on Physical and Functional Transduction
- Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
- Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the βA(T87Q)-Globin Gene